OTLK
Outlook Therapeutics, Inc.Company Information
- Company Name
- Outlook Therapeutics, Inc.
- CIK
- CIK0001649989
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- OTLK: Nasdaq
- Fiscal Year End
- September 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- OTLK
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-14
- Last sale
- —
- Shares purchased (TTM)
- 12,003,058
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 19,462,049
- Shares outstanding
- 136,743,333
- Ownership
- 14.23%
Earnings Market Reaction
- Filing date
- 2026-08-18
- Price on filing date
- —
- 1-month reaction
- -5.71%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Series A1 Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Series B Preferred Stock | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Cash And Cash Equivalents At Carrying Value | 11 | 8 | 9 | 8 | 9 | 8 | 6 | 15 | 32 | 47 | 10 | 23 | ||||||
| Accounts Receivable Net Current | 2 | 3 | 0 | 1 | 2 | - | - | - | - | - | - | - | ||||||
| Inventory Net | 5 | 3 | 3 | 3 | 4 | 4 | 3 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 5 | 7 | 5 | 4 | 6 | 7 | 7 | 12 | 14 | 11 | 10 | 8 | ||||||
| Assets Current | 23 | 21 | 17 | 17 | 21 | 18 | 16 | 27 | 46 | 58 | 20 | 31 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Equity Method Investments | 3 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Assets | 26 | 22 | 18 | 19 | 22 | 19 | 17 | 29 | 47 | 59 | 22 | 32 | ||||||
Liabilities Current | ||||||||||||||||||
| Notes And Loans Payable Current | - | 10 | 37 | 30 | 14 | 12 | 31 | 29 | 32 | 45 | 37 | 36 | ||||||
| Finance Lease Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Unsecured Debt Current | 18 | 6 | - | - | - | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Accounts Payable Current | 7 | 14 | 7 | 10 | 10 | 8 | 12 | 8 | 6 | 4 | 3 | 7 | ||||||
| Accrued Liabilities Current | 3 | 9 | 5 | 5 | 5 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | ||||||
| Accrued Income Taxes Current | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Liabilities Current | 29 | 39 | 49 | 46 | 31 | 25 | 48 | 43 | 43 | 54 | 46 | 47 | ||||||
| Long Term Notes And Loans | - | 11 | - | - | 20 | 21 | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Warrants And Rights Outstanding | 8 | 1 | 8 | 5 | 7 | 5 | 19 | 59 | 88 | 139 | 0 | 0 | ||||||
| Liabilities | 37 | 51 | 57 | 51 | 60 | 52 | 67 | 102 | 131 | 193 | 46 | 47 | ||||||
Temporary Equity | ||||||||||||||||||
| Common Stock Value | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | ||||||
| Additional Paid In Capital Common Stock | 641 | 603 | 590 | 573 | 555 | 539 | 475 | 470 | 465 | 459 | 452 | 453 | ||||||
| Retained Earnings Accumulated Deficit | -654 | -633 | -629 | -606 | -592 | -572 | -526 | -543 | -549 | -593 | -479 | -468 | ||||||
| Stockholders Equity | -10 | -29 | -39 | -32 | -37 | -32 | -50 | -73 | -84 | -134 | -24 | -14 | ||||||
| Liabilities And Stockholders Equity | 26 | 22 | 18 | 19 | 22 | 19 | 17 | 29 | 47 | 59 | 22 | 32 | ||||||
| Series A Preferred Stock | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 7 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 260 | 260 | 260 | 260 | 260 | 60 | 60 | 260 | 60 | 21 | 425 | 60 | ||||||
| Common Stock Shares Issued | 187 | 105 | 65 | 54 | 43 | 33 | 25 | 24 | 23 | 22 | 13 | 13 | ||||||
| Shares Outstanding | 187 | 105 | 65 | 54 | 43 | 33 | 25 | 24 | 23 | 22 | 13 | 13 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialOutlook Therapeutics, Inc. (OTLK) — SEC Financial Statements & Analysis
Outlook Therapeutics, Inc. (OTLK) is a biological products, (no diagnostic substances) company, incorporated in DE. Outlook Therapeutics, Inc. trades on Nasdaq as: OTLK. Outlook Therapeutics, Inc. (OTLK)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-18. Based on that filing, Outlook Therapeutics, Inc. carries a market cap of $217.42M, a P/E ratio of -3.56x, a P/B ratio of -20.92x, a P/S ratio of -2368.77x, an enterprise value of $224.41M, and an EV/EBITDA multiple of -4.04x. On profitability, it posts a gross margin of 2479.56%, an operating margin of 60613.98%, a net margin of 66592.50%, a Return on Equity (ROE) of 256.92%, and a Return on Assets (ROA) of -251.66%. Per share, it reports EPS of $-0.45, diluted EPS of $-0.45, free cash flow per share of $-0.41, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -106.10% year-over-year, net income growth of 40.70% year-over-year, and EPS growth of -61.97% year-over-year. On the balance sheet, it maintains a current ratio of 0.81x, a quick ratio of 0.45x, working capital of $-5.51M, a debt-to-equity ratio of -3.52x, a debt ratio of 1.4, an interest coverage ratio of -210.61x, free cash flow of $-56.15M (TTM), and net debt of $6.98M. Figures sourced from SEC EDGAR.
- Market Cap
- $217.42M
- P/E TTM
- -3.56x
- EPS TTM
- $-0.45
- P/B TTM
- -20.92x
- ROE TTM
- 256.92%
- ROA TTM
- -251.66%
- Debt To Equity
- -3.52x
- Free Cash Flow TTM
- $-56.15M
- Net Revenue TTM Growth 1Y
- -106.10%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Outlook Therapeutics, Inc. in?
Outlook Therapeutics, Inc. (OTLK) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does OTLK trade on?
Outlook Therapeutics, Inc. (OTLK) trades on the Nasdaq.
Where is Outlook Therapeutics, Inc. incorporated?
Outlook Therapeutics, Inc. is incorporated in DE.
When was Outlook Therapeutics, Inc. (OTLK)'s most recent SEC filing?
Outlook Therapeutics, Inc. (OTLK)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-18.
What is OTLK's market cap?
Outlook Therapeutics, Inc. (OTLK) has a market capitalization of $217.42M as of 2026-06-30.
What is OTLK's EPS (earnings per share)?
Outlook Therapeutics, Inc. (OTLK)'s trailing twelve month EPS is $-0.45 as of 2026-06-30.
What is OTLK's ROE (return on equity)?
Outlook Therapeutics, Inc. (OTLK)'s trailing twelve month Return on Equity (ROE) is 256.92% as of 2026-06-30.
What is OTLK's ROA (return on assets)?
Outlook Therapeutics, Inc. (OTLK)'s trailing twelve month Return on Assets (ROA) is -251.66% as of 2026-06-30.
What is OTLK's EV/EBITDA?
Outlook Therapeutics, Inc. (OTLK)'s trailing twelve month EV/EBITDA is -4.04x as of 2026-06-30.